ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,096 | -99.7% | 27,326 | +158.8% | 0.11% | +86.2% |
| Q3 2022 | $437,000 | -65.3% | 10,560 | -39.1% | 0.06% | -65.7% |
| Q1 2022 | $1,260,000 | -28.5% | 17,345 | -17.2% | 0.17% | -23.5% |
| Q4 2021 | $1,762,000 | +312.6% | 20,950 | +579.3% | 0.22% | +215.7% |
| Q4 2020 | $427,000 | -1.4% | 3,084 | -69.6% | 0.07% | +40.0% |
| Q4 2019 | $433,000 | +27.4% | 10,129 | +27.3% | 0.05% | +8.7% |
| Q3 2019 | $340,000 | +69.2% | 7,959 | +174.4% | 0.05% | +130.0% |
| Q1 2019 | $201,000 | -75.3% | 2,900 | -72.6% | 0.02% | -50.0% |
| Q2 2018 | $813,000 | -9.4% | 10,582 | -39.9% | 0.04% | -14.9% |
| Q1 2018 | $897,000 | -28.5% | 17,600 | +57.3% | 0.05% | -23.0% |
| Q4 2015 | $1,255,000 | +30.7% | 11,188 | +12.2% | 0.06% | +29.8% |
| Q3 2015 | $960,000 | +6.5% | 9,970 | +13.3% | 0.05% | +34.3% |
| Q2 2015 | $901,000 | +184.2% | 8,800 | +72.5% | 0.04% | +169.2% |
| Q1 2015 | $317,000 | -32.8% | 5,100 | -52.5% | 0.01% | -60.6% |
| Q4 2014 | $472,000 | – | 10,748 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 497,899 | $31,617,000 | 3.20% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 390,453 | $24,794,000 | 1.81% |
| First Light Asset Management, LLC | 180,017 | $11,431,000 | 1.59% |
| Rock Springs Capital Management LP | 580,000 | $36,830,000 | 1.33% |
| Capital Impact Advisors, LLC | 36,165 | $2,244,000 | 0.82% |
| SECTOR GAMMA AS | 79,653 | $5,058,000 | 0.81% |
| Verity Asset Management, Inc. | 7,193 | $457,000 | 0.51% |
| Opus Point Partners Management, LLC | 5,064 | $322,000 | 0.48% |
| Capital International Sarl | 52,000 | $3,302,000 | 0.46% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 6,216 | $394,000 | 0.43% |